Orally deliverable lutein nanoparticles as robust ROS scavenger for dry eye disease by targeting Peyer’s patches and mitochondria of ocular cell

Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 494, P. 153024 - 153024

Published: June 10, 2024

Language: Английский

---

Consumption of Limosilactobacillus fermentum Inhibits Corneal Damage and Inflammation in Dry Eye Disease Mouse Model through Regulating the Gut Microbiome

International Journal of Molecular Sciences, Journal Year: 2024, Volume and Issue: 25(6), P. 3528 - 3528

Published: March 20, 2024

The present study investigated the effect of orally administered Limosilactobacillus fermentum HY7302 (HY7302) on relationship between ocular tissue and microbiome in a corneal injury dry eye mouse model. Specifically, 0.1% benzalkonium chloride (BAC) was applied to surface for 14 days induce male Balb/c mice. During BAC treatment period, (1 × 108 CFU/kg/day or 1 109 CFU/kg/day) an omega-3 positive control (400 mg/kg/day) were (n = eight/group). To examine signaling pathways affected by treatment, vitro effects tight junctions inflammatory response colon epithelial cell line, CMT-93. exposure decreased tear production, induced inflammation detachment, altered gut microbiota. However, oral administration restored secretion detachment BAC-treated Further, alleviated via modulation matrix metalloproteinase-9 (MMP-9) expression affeted alterations microbiota composition. These findings suggest that gut-eye axis interaction affects disease severity injury, alteration could improve health regulating response.

Language: Английский

---

Molecular Mechanisms and Therapeutic Potential of Gabapentin with a Focus on Topical Formulations to Treat Ocular Surface Diseases

Pharmaceuticals, Journal Year: 2024, Volume and Issue: 17(5), P. 623 - 623

Published: May 11, 2024

Gabapentin (GBP) was originally developed as a potential agonist for Gamma-Amino-Butyric-Acid (GABA) receptors, aiming to inhibit the activation of pain-signaling neurons. Contrary initial expectations, it does not bind GABA receptors. Instead, exhibits several distinct pharmacological activities, including: (1) binding alpha-2-delta protein subunit voltage-gated calcium channels in central nervous system, thereby blocking excitatory influx calcium; (2) reducing expression and phosphorylation CaMKII via modulation ERK1/2 phosphorylation; (3) inhibiting glutamate release interfering with NMDA receptors; (4) enhancing synthesis; (5) increasing cell-surface δGABA_A contributing its antinociceptive, anticonvulsant, anxiolytic-like effects. Additionally, GBP displays (6) inhibition NF-kB subsequent production inflammatory cytokines, (7) stimulation purinergic adenosine A1 receptor, which supports anti-inflammatory wound-healing properties. Initially approved treating seizures postherpetic neuralgia, is now broadly used various conditions, including psychiatric disorders, acute chronic neuropathic pain, sleep disturbances. Recently, an eye drop formulation, has also been explored therapeutic option ocular surface discomfort conditions such dry eye, neurotrophic keratitis, corneal ulcers, pain. This review aims summarize evidence supporting molecular effects GBP, special emphasis on applications diseases.

Language: Английский

---

Controlled release of vitamin A palmitate from crosslinked cyclodextrin organic framework for dry eye disease therapy

International Journal of Pharmaceutics, Journal Year: 2024, Volume and Issue: 659, P. 124279 - 124279

Published: May 26, 2024

Language: Английский

---

A multifunctional nanoplatform with dual-targeted antibacterial and cascaded immunomodulatory strategy for the treatment of bacterial keratitis

Chemical Engineering Journal, Journal Year: 2024, Volume and Issue: 498, P. 155323 - 155323

Published: Aug. 30, 2024

Language: Английский

---